A new ADC biotech looks to revive secretive platform, secures Big VC backing

Paul Schloesser

Associate Editor

With many companies working with antibody-drug conjugates in cancer, the newest one has two substantial backers and is looking to revitalize an old platform. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

A new ADC biotech looks to revive secretive platform, secures Big VC backing

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

A new ADC biotech looks to re­vive se­cre­tive plat­form, se­cures Big VC back­ing

Associate Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

A new ADC biotech looks to revive secretive platform, secures Big VC backing